Group One Trading’s Janux Therapeutics JANX Stock Holding History

Group One Trading’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36.9K	Sell	2,400 -9,600	-80%	-$139K	﹤0.01%	5598
2026 Q1	$167K	Buy	12,000 +1,800	+18%	+$24.7K	﹤0.01%	4270
2025 Q4	$141K	Buy	10,200 +8,500	+500%	+$200K	﹤0.01%	4690
2025 Q3	$41.5K	Sell	1,700 -300	-15%	-$7.31K	﹤0.01%	6125
2025 Q2	$46.2K	Sell	2,000 -4,800	-71%	-$126K	﹤0.01%	5643
2025 Q1	$184K	Sell	6,800 -600	-8%	-$22.6K	﹤0.01%	4090
2024 Q4	$396K	Buy	7,400 +3,700	+100%	+$196K	﹤0.01%	3368
2024 Q3	$168K	Buy	3,700 +1,200	+48%	+$52.2K	﹤0.01%	3780
2024 Q2	$105K	Buy	2,500 +1,400	+127%	+$65.7K	﹤0.01%	3928
2024 Q1	$41.4K	Buy	+1,100	New	+$24K	﹤0.01%	4867

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Group One Trading's JANX Position: Q2 2026 in Review

Group One Trading reduced its Janux Therapeutics (JANX) stake by 78% in Q2 2026, selling an estimated $6.72K and leaving 128 shares worth $1.97K. The position accounts for ﹤0.01% of the portfolio, ranked #7043.

Group One Trading first reported a position in JANX in Q2 2024 and has held it in 6 quarters since. The position peaked at $351K in Q1 2025. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Group One Trading held 128 shares of Janux Therapeutics worth $1.97K as of Q2 2026.
Group One Trading sold 464 Janux Therapeutics shares in Q2 2026, an estimated $6.72K.
Janux Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #7043 holding.
Group One Trading first reported a position in Janux Therapeutics in Q2 2024 and has held it in 6 quarters since.
Group One Trading's Janux Therapeutics position peaked at $351K in Q1 2025.
197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.